Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia

Mycoses

Volumn 55, Issue 3, 2012, Pages 244-256

  Al Badriyeh, Daoud ^a,b   Liew, Danny ^c   Stewart, Kay ^b   Kong, David C M ^b  

^a Qatar University ^*  (Qatar)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Caspofungin; Cost benefit; Economic; Empiric; Model; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; AUSTRALIA; CANDIDIASIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DEATH; DRUG COST; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; FUSARIOSIS; HUMAN; MAJOR CLINICAL STUDY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TRICHOSPORONOSIS; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; AUSTRALIA; ECHINOCANDINS; ECONOMICS, PHARMACEUTICAL; FEVER; HUMANS; MALE; NEUTROPENIA; PYRIMIDINES; TRIAZOLES;

EID: 84859939843     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02074.x     Document Type: Article

References (29)

1. Dixon S, McKeen E, Tabberer M et al. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics 2004; 22: 421-33.
2. Moeremans K, Annemans L. Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients. Expert Opin Pharmacother 2006; 7: 1931-43.
3. Martino R, Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 2006; 132: 138-54.
4. Rotstein C. Empiric antifungal therapy in neutropenic cancer patients. Curr Infect Dis Rep 2006; 8: 7-13.
5. Herbrecht R, Nivoix Y, Fohrer C et al. Management of systemic fungal infections: alternatives to itraconazole. J Antimicrob Chemother 2005; 56(Suppl. 1): i39-48.
6. Marchettia O, Cordonnierb C, Calandraa T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. EJC 2007; 5: 32-42.
7. Potter M. Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemother 2005; 56(Suppl. 1): i49-54.
8. Dominguez-Gil A, Martin I, Garcia Vargas M. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Clin Drug Investig 2007; 27: 197-205.
9. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
10. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
11. Slavin MA, Szer J, Grigg AP et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 2004; 34: 192-200.
12. Slavin MA, Szer J, Morrissey O et al. Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2008. Intern Med J 2008; 38: 457-67.
13. Lilford RJ, Pauker SG, Braunholtz DA et al. Getting research findings into practice: decision analysis and the implementation of research findings. BMJ 1998; 317: 405-9.
14. Australian Bureau of Statistics. National Health Survey: Summary of Results. 2005 (accessed on 17 June 2010).
15. Health Purchasing Victoria. Health Purchasing Victoria Tender. 2009 (accessed on 29 October 2010).
16. Australian Government of Health and Ageing. National Hospital Cost Data Collection. Round 11 (2008-09) Cost Report version 6. (accessed on 29 October 2010).
17. Australian Bureau of Statistics. Consumer Price Index. 2010 (accessed on 4 December 2010).
18. Australian Government of Health and Ageing. Medicare Benefits Schedule Book. 2009 (accessed on 29 October 2010).
19. O'Hagan A, Stevenson M, Madan J. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. Health Econ 2007; 16: 1009-23.
20. Drummond MF, O'Brien B, Stoddart GL et al. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. New York: Oxford University Press, 2000.
21. Petitti DB. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis, 2nd edn. New York: Oxford University Press, 2000.
22. Nixon J, Stoykova B, Glanville J et al. The U.K. NHS economic evaluation database. Economic issues in evaluations of health technology. Int J Technol Assess Health Care 2000; 16: 731-42.
23. Jain S, Arora NK. Randomized controlled trial and economic evaluation. Indian J Pediatr 2000; 67: 363-8.
24. Sculpher MJ, Claxton K, Drummond M et al. Whither trial-based economic evaluation for health care decision making? Health Econ 2006; 15: 677-87.
25. Bennett JE, Powers J, Walsh T et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003; 36(Suppl. 3): 117-22.
26. Ferrara JJ, MacDougall C, Gallagher JC. Empiric antifungal therapy in patients with febrile neutropenia: factors to consider when evaluating the literature. Pharmacotherapy 2011; 31: 369-85.
27. Powers JH. Empirical antifungal therapy in febrile neutropenic patients: caution about composite end points and the perils of p value. CID 2004; 39: 1738-9.
28. Rechner IJ, Lipman J. The costs of caring for patients in a tertiary referral Australian Intensive Care Unit. Anaesth Intensive Care 2005; 33: 477-82.
29. La CC, Tan CK, Huang YT et al. Current challenges in the management of invasive fungal infections. J Infect Chemother 2008; 14: 77-85.